Answers are grounded in this paper and cite their sources.
Amyotrophic lateral sclerosis (ALS) remains a fatal neurodegenerative disease with limited disease-modifying options, and effective delivery of therapeutics to the central nervous system is hindered by the blood–brain barrier (BBB). Here, we report mesoporous silica nanoparticles (MSNs) designed as a combination-delivery platform integrating riluzole, 5-methoxytryptamine (5MT) as an antioxidant-related component, and glucosamine as a biomolecular surface coating. The resulting multifunctional nanosystems were prepared and characterized by complementary physicochemical techniques, supporting successful incorporation of the selected components within the MSN-based carrier. To obtain a first-pass indication of brain-oriented delivery feasibility, permeability was assessed using a PAMPA-BBB assay that mimics key features of the brain lipid environment. This screening assay showed formulation-dependent apparent silica carryover across the artificial lipid membrane and provides a basis for subsequent evaluation in cell-based BBB models, supporting their further evaluation as ALS-oriented nanodelivery candidates. Overall, these results establish a rational proof-of concept of MSN platform for combination delivery and provide a permeability-screening basis for subsequent studies in more advanced BBB and neurobiological models, supporting their further evaluation as multifunctional delivery platforms for neurodegenerative diseases, such as ALS.
No takes yet. Share an insight, caveat, or question.
Grasa-Gude et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: